News

Meta-060 is a proprietary and patented formulation of tetrahydro iso-alpha acids derived from hops. The collaboration is to investigate if genetic variations identified by Interleukin Genetics are beneficial

Resolor is a selective, high-affinity 5-HT4 receptor agonist specifically developed to target impaired motility associated with chronic constipation. Three Phase II dose-finding trials of 280 predominantly female patients

The Phase 3 trial investigated the safety and efficacy of TAK-085 in comparison with an active comparator, EPA (eicosapentaenoic acid) in patients suffering from hypertriglyceridemia. The results of

In two Phase 3 trials for the treatment of CDI, fidaxomicin was non-inferior in clinical cure when compared to vancomycin, the only FDA approved product for CDI. The

As per the terms of the research collaboration and option agreement, Pepscan will utilize its Chemical LInkage of Peptides onto Scaffolds (CLIPS) technology for optimizing novel therapeutic Phylomer

The company is engaged in the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology in the areas of functional proteomics, drug development and development of biomarkers.

Regorafenib is indicated as a treatment for patients who are suffering from metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite at least imatinib and

Typical applications range from small-scale protein expression to media or process optimization studies UniVessel SU is made up of USP class VI conform polycarbonate and is suitable for

The company has reported a net loss of $1.22m, or $0.02 loss per diluted share, compared to net loss of $1.05m or $0.02 loss per diluted share, for